<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740425</url>
  </required_header>
  <id_info>
    <org_study_id>TRITAVI18</org_study_id>
    <nct_id>NCT03740425</nct_id>
  </id_info>
  <brief_title>Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study</brief_title>
  <acronym>TRITAVI</acronym>
  <official_title>Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periprocedural bleeding events are frequent during transcatheter aortic valve implantation
      (TAVI), mainly driven by vascular complications and are associated to a worse prognosis.
      Therefore, red blood cell (RBC) transfusion is often required, although it is associated with
      worsened outcomes.

      There is no consensus on the optimal transfusion strategy after bleeding. The Transfusion
      Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) will be a multicenter
      retrospective registry enrolling consecutive patients who underwent TAVI; the primary aim of
      the study will be to test whether RBC transfusion is a marker or an independent predictor of
      adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periprocedural bleeding events are frequent during transcatheter aortic valve implantation
      (TAVI), mainly driven by vascular complications and are associated to a worse prognosis.
      Therefore, red blood cell (RBC) transfusion is often required, although it is associated with
      worsened outcomes.

      There is no consensus on the optimal transfusion strategy after bleeding: among patients
      undergoing cardiac surgery, the Transfusion Requirements in Cardiac Surgery (TRICS) III trial
      documented that a restrictive RBC transfusion strategy (if hemoglobin level was &lt;7.5 g/dl)
      was noninferior to a liberal approach (if hemoglobin level was &lt;9.5 g/dl) with respect to the
      composite occurrence of death, myocardial infarction (MI), stroke, or new-onset renal failure
      with dialysis.

      The Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) will be a
      multicenter retrospective registry enrolling consecutive patients who underwent TAVI; the
      primary aim of the study will be to test whether RBC transfusion is a marker or an
      independent predictor of adverse events. Patients will be stratified according to their
      lowest hemoglobin value (&gt;9.5 g/dl, 7.5-9.5 g/dl and &lt;7.5 g/dl) and to whether they received
      or not periprocedural RBC transfusion.

      The primary endpoint will be the 30-day occurrence of major adverse cardiovascular events
      (MACE), as death, myocardial infarction (MI), stroke, or acute kidney injury (AKI, as
      absolute increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50% increase ≤72 hours).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>30 days and end of follow-up (3 years)</time_frame>
    <description>all-cause death, myocardial infarction (MI), stroke, or acute kidney injury (AKI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days and end of follow-up (3 years)</time_frame>
    <description>all-cause death, cardiovascular death, non cardiovascular death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and end of follow-up (3 years)</time_frame>
    <description>Myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>acute kidney injury (AKI)</measure>
    <time_frame>30 days</time_frame>
    <description>need for dialYsis or increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50% increase ≤72 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>stroke</measure>
    <time_frame>30 days and end of follow-up (3 years)</time_frame>
    <description>stroke or transient ischemic attack (TIA)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3235</enrollment>
  <condition>Transcatheter Aortic Valve Implantation (TAVI)</condition>
  <condition>Blood Transfusion</condition>
  <condition>AKI</condition>
  <condition>Prognosis</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Transfusion</arm_group_label>
    <description>Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Transfusion</arm_group_label>
    <description>Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Transfusion</intervention_name>
    <description>Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)</description>
    <arm_group_label>No Transfusion</arm_group_label>
    <arm_group_label>Transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-consecutive patients referring at the participants centers undergoing transcatheter
        aortic valve implantation (TAVI)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing transcatheter aortic valve implantation (TAVI)

        Exclusion Criteria:

          -  age&lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Zimarino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. d'Annunzio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santissima Annunziata Hospital</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. N Engl J Med. 2017 Nov 30;377(22):2133-2144. doi: 10.1056/NEJMoa1711818. Epub 2017 Nov 12.</citation>
    <PMID>29130845</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazer CD, Whitlock RP, Fergusson DA, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, Carrier FM, McGuinness S, Young PJ, Byrne K, Villar JC, Royse A, Grocott HP, Seeberger MD, Mehta C, Lellouche F, Hare GMT, Painter TW, Fremes S, Syed S, Bagshaw SM, Hwang NC, Royse C, Hall J, Dai D, Mistry N, Thorpe K, Verma S, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018 Sep 27;379(13):1224-1233. doi: 10.1056/NEJMoa1808561. Epub 2018 Aug 26.</citation>
    <PMID>30146969</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 10, 2018</study_first_submitted>
  <study_first_submitted_qc>November 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Marco Zimarino</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared only to other Participants Centers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

